Dual-targeting fluorous peptide proteolysis-targeting chimeras for cancer therapy
Journal of Controlled Release · 2026-03 · 391 · 114591
DOI: 10.1016/j.jconrel.2025.114591 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2026-03. Verfasst von Guangyu Rong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Eye & ENT Hospital, State Key Laboratory of Brain Function and Disorders, MOE Frontiers Center for Brain Science, Fudan …. Hauptthemen laut MEDLINE: Peptides, bcl-X Protein, Melanoma, Experimental, B7-H1 Antigen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Shanghai Rising-Star Program, National Science Fund for Distinguished Young Scholars, East China Normal University.
Abstract (Originalsprache)
Proteolysis-targeting chimeras (PROTACs) offer a powerful strategy for degrading disease-causing proteins. Simultaneous degradation of two oncogenic proteins by PROTACs can yield synergistic therapeutic effects. Here, we developed a dual-targeting fluorous peptide-based PROTAC (DFP-PROTAC) that leverages supramolecular self-assembly for cancer therapy. By conjugating PD-L1- and Bcl-xL-binding peptides to fluorous tags, we generated carrier-free nanoparticles that enter cells via macropinocytosis and achieve efficient endosomal escape, mediating simultaneous degradation of both extracellular PD-L1 and cytosolic Bcl-xL through the ubiquitin-proteasome system. Our results demonstrate that DFP-PROTAC coordinately restores antitumor immunity and apoptotic sensitivity while achieving superior antitumor efficacy with excellent biocompatibility in B16-F10 melanoma-bearing mice, highlighting its therapeutic potential for cancer treatment. This modular fluorous platform offers a versatile strategy for degrading multiple protein targets in the treatment of various diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Eye & ENT Hospital, State Key Laboratory of Brain Function and Disorders, MOE Frontiers Center for Brain Science, Fudan University, Shanghai 200031, China.
- Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, Shanghai 200241, China.
- Department of Musculoskeletal Oncology, Fudan University, Shanghai Cancer Center, Shanghai 200032, China. Electronic address: specialsamsun@126.com.
- Department of Ophthalmology, Eye & ENT Hospital, State Key Laboratory of Brain Function and Disorders, MOE Frontiers Center for Brain Science, Fudan University, Shanghai 200031, China; National Health Commission of Myop…
- Department of Ophthalmology, Eye & ENT Hospital, State Key Laboratory of Brain Function and Disorders, MOE Frontiers Center for Brain Science, Fudan University, Shanghai 200031, China; Shanghai Frontiers Science Center…
Förderung
- Shanghai Rising-Star Program
- National Science Fund for Distinguished Young Scholars
- East China Normal University
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Shanghai Health and Medical Development Foundation
Zitieren
APA
Rong, G., Li, Y., Zhu, F., Lu, Y., Sun, Z., Hong, J., & Cheng, Y. (2026). Dual-targeting fluorous peptide proteolysis-targeting chimeras for cancer therapy. Journal of Controlled Release, 391, 114591. https://doi.org/10.1016/j.jconrel.2025.114591
Vancouver
Rong G, Li Y, Zhu F, Lu Y, Sun Z, Hong J, et al. Dual-targeting fluorous peptide proteolysis-targeting chimeras for cancer therapy. Journal of Controlled Release. 2026;391:114591. doi:10.1016/j.jconrel.2025.114591
BibTeX
@article{Rong2026,
author = {Rong, Guangyu and Li, Yuhan and Zhu, Fang and Lu, Yiteng and Sun, Zhengwang and Hong, Jiaxu and Cheng, Yiyun},
title = {Dual-targeting fluorous peptide proteolysis-targeting chimeras for cancer therapy},
journal = {Journal of Controlled Release},
year = {2026},
volume = {391},
pages = {114591},
doi = {10.1016/j.jconrel.2025.114591}
}
EUVIMED